Mereo BioPharma Group plc

Equities

MREO

US5894921072

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-22 EDT			5-day change	1st Jan Change
2.99 ^USD	-1.64%		-5.68%	+29.44%

05-22	European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading	MT
05-17	European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Friday Trading	MT

Richard Bungay to Leave Mereo BioPharma Group plc as Chief Financial Officer and Chief Operating Officer in April 2017

October 05, 2016 at 02:00 am

Mereo BioPharma Group plc announced that Richard Bungay, the company's Chief Financial Officer and Chief Operating Officer, will be leaving Mereo in order to pursue other business interests. Richard will be leaving in April 2017 in order to ensure an orderly transition.

Latest news about Mereo BioPharma Group plc

European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading	05-22	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Friday Trading	05-17	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading	05-16	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading; End Week Up Nearly 3%	05-10	MT
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Set to Close Week Lower	05-03	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Lower in Wednesday Trading	05-01	MT
European Equities Traded in the US as American Depositary Receipts Decline	04-30	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.4%	04-26	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	04-24	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	04-09	MT
European Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading	04-08	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading	04-03	MT
European Equities Traded in the US as American Depositary Receipts Start Week Modestly Higher	04-01	MT
European Equities Traded in the US as American Depositary Receipts Slightly Higher Thursday	03-28	MT
Needham Adjusts Price Target on Mereo BioPharma to $6 From $5, Keeps Buy Rating	03-28	MT
Mereo BioPharma Group plc Reports Earnings Results for the Full Year Ended December 31, 2023	03-27	CI
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading	03-25	MT
European Equities Traded in the US as American Depositary Receipts Slightly Higher in Friday Trading	03-22	MT
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	03-21	MT
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Friday Trading	03-15	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading	02-29	MT
European Equities Traded in the US as American Depositary Receipts Rise Friday, Set to End Week Up 1.5%	02-23	MT
European Equities Traded in the US as American Depositary Receipts Kick Off Week Lower in Monday Trading	02-05	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Friday Trading But End Week Higher	02-02	MT
European Equities Traded in the US as American Depositary Receipts Make Modest Gains in Thursday Trading	02-01	MT

Chart Mereo BioPharma Group plc

Duration

Period

More charts

Company Profile

Mereo BioPharma Group plc is a biopharmaceutical company. It is focused on the development of therapeutics for rare diseases. It has developed a portfolio of clinical-stage product candidates. The Company has two rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for the treatment of severe alpha-1-antitrypsin deficiency-associated lung disease (AATD-LD) and bronchiolitis obliterans syndrome (BOS). It also has two oncology product candidates in clinical development. It also includes Etigilimab, an antibody against TIGIT (T-cell immunoreceptor with Ig and ITIM domains). Its non-core partnered programme, Navicixizumab, is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Its non-core programs available for partnership include Acumapimod and Leflutrozole. Acumapimod is a p38 MAP kinase inhibitor therapy for treatment during severe acute exacerbations of COPD (AECOPD).

Sector

Biotechnology & Medical Research

Calendar

2024-09-16 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Mereo BioPharma Group plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.349 GBP

Average target price

4.959 GBP

Spread / Average Target

+111.09%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MEREO BIOPHARMA GROUP PLC	+29.44%	419M
VERTEX PHARMACEUTICALS INCORPORATED	+9.99%	115B
REGENERON PHARMACEUTICALS, INC.	+12.01%	106B
BIONTECH SE	-3.07%	24.69B
ARGENX SE	-0.67%	21.97B
GENMAB A/S	-4.64%	19.27B
BEIGENE, LTD.	-6.90%	17.56B
WUXI APPTEC CO., LTD.	-39.36%	17.32B
NEUROCRINE BIOSCIENCES, INC.	+5.82%	14.03B
SAREPTA THERAPEUTICS, INC.	+33.05%	12.13B

Bio Therapeutic Drugs